The startup develops lipid nanoparticle delivery systems specifically designed for nucleic acid therapeutics, enhancing drug stability and bioavailability. This technology improves therapeutic efficacy while reducing side effects, enabling more effective genomic medicine applications.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The effective delivery of nucleic acid therapeutics, such as mRNA and siRNA, is hindered by their instability and poor cellular uptake. Traditional delivery methods often lack the precision and efficiency needed to reach target cells, limiting therapeutic efficacy and potentially causing off-target effects.
Solution
Adalid Sciences develops novel lipid nanoparticle (LNP) delivery systems designed to enhance the stability, bioavailability, and targeted delivery of nucleic acid therapeutics. Their LNP technology utilizes structurally novel lipids, including adamantane-core lipids, to improve drug delivery and therapeutic outcomes. Through custom formulation, rigorous testing, and optimization, Adalid Sciences engineers LNPs for specific drug candidates, ensuring optimal performance, safety, and efficacy. They offer consultation, formulation, optimization, and support services to seamlessly integrate their LNP technology into clients' workflows.
Target Audience
Adalid Sciences serves biotechnology and pharmaceutical companies, CROs, CMOs, service providers, and academic institutions involved in developing genomic therapies and nucleic acid-based therapeutics.
Features
- Structurally novel lipid nanoparticles based on an adamantane core
- Over 150 novel ionizable lipidoids synthesized and characterized
- In vivo data demonstrating safety and efficacy for nucleic acid delivery
- Customizable LNP formulation for various nucleic acids (siRNA, mRNA, DNA plasmids, miRNA)
- Analytical and biophysical characterization, including LNP size, surface charge, and cryo-electron microscopy
- Preclinical characterization, including pharmacodynamic and safety/tolerability studies
- Synthetic process technology transfer to Contract Research Organizations (CROs)